Proactive Health Testing FAQs
MyOme's Proactive Health tests use whole genome sequencing to deliver single-gene analysis, polygenic risk scores, and medication insights to guide lifestyle choices, screening, and treatment options.
- What is MyOme Proactive Health?
- How is this Proactive Health test different from other genetic tests?
- What is polygenic risk?
- What are some examples of conditions included in the Single-Gene Risk™ analysis?
- What affects how someone responds to medication?
- What does the Proactive Health test include?
- What is the Single-Gene Risk Test?
- Why do changes in a single gene matter?
- What is our Single-Gene Risk test?
- What is our iPRS™ for Coronary Artery Disease (CAD) test?
- What is our Medication Response test?
- What is our iPRS™ for breast cancer test?
- How can knowing someone’s Integrated Risk Score for type 2 diabetes help?
- Where can I find more information on type 2 diabetes genetics and risk?
- What is our Type 2 Diabetes (T2D) test?
- What impacts the risk for type 2 diabetes?
- How does the T2D iPRS help determine a person’s risk?
- What is the iPRS™ test for prostate cancer?
- Who is the Prostate Cancer iPRS™ test for?
- How can knowing someone’s iPRS™ for prostate cancer help?
- Does a high iPRS™ mean someone will develop prostate cancer?
- How can someone use their iPRS™ results with their provider?
- What impacts the risk for prostate cancer?
- How does the Prostate Cancer iPRS™ determine a person’s risk?
- How will risk be communicated on the Prostate Cancer iPRS™ report?
- Where can I find more information on prostate cancer and screening?
- What are some example medications and genes in the Medication Response test?